Literature DB >> 19727679

Further evidence of association between amphetamine response and SLC6A2 gene variants.

Andrea M Dlugos1, Ajna Hamidovic, Abraham A Palmer, Harriet de Wit.   

Abstract

BACKGROUND AND RATIONALE: We previously found that the intronic norepinephrine transporter gene (SLC6A2) polymorphism rs36017 modulates feelings of elation after administration of 20 mg D-amphetamine in healthy volunteers.
OBJECTIVES: In this study, we further investigated the association between D-amphetamine response and 11 SLC6A2 single-nucleotide polymorphisms (SNPs), including rs36017, in an extended sample of Caucasian young adults.
METHODS: One hundred fifty-nine healthy volunteers participated in a three-session double-blind crossover design receiving either placebo or oral D-amphetamine (10 and 20 mg). Based on our previous results, we examined the associations between levels of self-reported elation and vigor after D-amphetamine administration and SNPs and SNP haplotypes in SLC6A2.
RESULTS: Consistent with our previous findings, SNPs rs36017 and rs1861647 were associated with significantly higher ratings of elation and vigor after 20 mg Damphetamine. Ratings of vigor after 20 mg D-amphetamine were also associated with a two-SNP haplotype formed with rs1861647 and rs5569 and a three-SNP haplotype formed with rs36017, rs10521329, and rs3785155.
CONCLUSIONS: These results provide further evidence that genetic variants in the SLC6A2 gene are involved in acute response to D-amphetamine, which may influence progression to amphetamine abuse. Identifying sources of variation in acute drug responses could lead to better prevention and treatment of psychostimulant abuse and may be valuable in the therapeutic use of stimulants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19727679      PMCID: PMC4242585          DOI: 10.1007/s00213-009-1628-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

1.  Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants.

Authors:  Christa Hohoff; Jennifer M McDonald; Bernhard T Baune; Edwin H Cook; Jürgen Deckert; Harriet de Wit
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

2.  Chamber-specific alterations of norepinephrine uptake sites in cardiac hypertrophy.

Authors:  M Böhm; M Castellano; M Flesch; C Maack; M Moll; M Paul; F Schiffer; O Zolk
Journal:  Hypertension       Date:  1998-11       Impact factor: 10.190

3.  Norepinephrine transporter (NET) promoter and 5'-UTR polymorphisms: association analysis in panic disorder.

Authors:  Yoo J Lee; Christa Hohoff; Katharina Domschke; Philipp Sand; Gregor Kuhlenbäumer; Anja Schirmacher; Christine M Freitag; Jobst Meyer; Gerald Stöber; Petra Franke; Markus M Nöthen; Jürgen Fritze; Rolf Fimmers; Henk S Garritsen; Florian Stögbauer; Jürgen Deckert
Journal:  Neurosci Lett       Date:  2004-12-15       Impact factor: 3.046

4.  Cannabinoid receptor gene (CNR1): association with i.v. drug use.

Authors:  D E Comings; D Muhleman; R Gade; P Johnson; R Verde; G Saucier; J MacMurray
Journal:  Mol Psychiatry       Date:  1997-03       Impact factor: 15.992

5.  Dopamine transporter gene associated with diminished subjective response to amphetamine.

Authors:  David C Lott; Soo-Jeong Kim; Edwin H Cook; Harriet de Wit
Journal:  Neuropsychopharmacology       Date:  2005-03       Impact factor: 7.853

6.  Positive association between T-182C polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a japanese population.

Authors:  Kazuyuki Inoue; Kunihiko Itoh; Keizo Yoshida; Tetsuo Shimizu; Toshio Suzuki
Journal:  Neuropsychobiology       Date:  2004       Impact factor: 2.328

7.  Adverse effects of stimulant drugs in a community sample of drug users.

Authors:  S Williamson; M Gossop; B Powis; P Griffiths; J Fountain; J Strang
Journal:  Drug Alcohol Depend       Date:  1997-03-14       Impact factor: 4.492

8.  Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart.

Authors:  P Merlet; F Pouillart; J L Dubois-Randé; N Delahaye; R Fumey; A Castaigne; A Syrota
Journal:  J Nucl Med       Date:  1999-02       Impact factor: 10.057

9.  Gene expression differences in mice divergently selected for methamphetamine sensitivity.

Authors:  Abraham A Palmer; Miguel Verbitsky; Rathi Suresh; Helen M Kamens; Cheryl L Reed; Na Li; Sue Burkhart-Kasch; Carrie S McKinnon; John K Belknap; T Conrad Gilliam; Tamara J Phillips
Journal:  Mamm Genome       Date:  2005-05       Impact factor: 2.957

10.  Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity.

Authors:  R R Gainetdinov; W C Wetsel; S R Jones; E D Levin; M Jaber; M G Caron
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

View more
  12 in total

1.  Temperament and externalizing behavior as mediators of genetic risk on adolescent substance use.

Authors:  Elisa M Trucco; Brian M Hicks; Sandra Villafuerte; Joel T Nigg; Margit Burmeister; Robert A Zucker
Journal:  J Abnorm Psychol       Date:  2016-02-04

2.  Involvement of threonine 258 and serine 259 motif in amphetamine-induced norepinephrine transporter endocytosis.

Authors:  Balasubramaniam Annamalai; Padmanabhan Mannangatti; Obulakshmi Arapulisamy; Sammanda Ramamoorthy; Lankupalle D Jayanthi
Journal:  J Neurochem       Date:  2010-07-30       Impact factor: 5.372

Review 3.  Genetic factors modulating the response to stimulant drugs in humans.

Authors:  Amy B Hart; Harriet de Wit; Abraham A Palmer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 4.  Monoamine transporters: vulnerable and vital doorkeepers.

Authors:  Zhicheng Lin; Juan J Canales; Thröstur Björgvinsson; Morgane Thomsen; Hong Qu; Qing-Rong Liu; Gonzalo E Torres; S Barak Caine
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

5.  Pharmacogenetics of stimulant abuse liability: association of CDH13 variant with amphetamine response in a racially-heterogeneous sample of healthy young adults.

Authors:  Adam M Leventhal; Matthew G Kirkpatrick; Mollie S Pester; John E McGeary; Robert M Swift; Steve Sussman; Christopher W Kahler
Journal:  Psychopharmacology (Berl)       Date:  2016-10-22       Impact factor: 4.530

6.  Network analysis of the genomic basis of the placebo effect.

Authors:  Rui-Sheng Wang; Kathryn T Hall; Franco Giulianini; Dani Passow; Ted J Kaptchuk; Joseph Loscalzo
Journal:  JCI Insight       Date:  2017-06-02

Review 7.  Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood.

Authors:  Zsofia Nemoda; Anna Szekely; Maria Sasvari-Szekely
Journal:  Neurosci Biobehav Rev       Date:  2011-04-15       Impact factor: 8.989

8.  Susceptibility loci for heroin and cocaine addiction in the serotonergic and adrenergic pathways in populations of different ancestry.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2015-07-31       Impact factor: 2.533

9.  OPRM1 gene variants modulate amphetamine-induced euphoria in humans.

Authors:  A M Dlugos; A Hamidovic; C Hodgkinson; P H Shen; D Goldman; A A Palmer; H de Wit
Journal:  Genes Brain Behav       Date:  2010-11-02       Impact factor: 3.449

10.  Candidate gene studies of a promising intermediate phenotype: failure to replicate.

Authors:  Amy B Hart; Harriet de Wit; Abraham A Palmer
Journal:  Neuropsychopharmacology       Date:  2012-12-03       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.